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Objective: This is a prospective trial comparing the impact of intraoperative ﬂexible, rigid, and no
cystoscopy on dysuria immediately after permanent seed prostate brachytherapy (PB). It prospectively
documents the time course and characteristics of dysuria, as well as the rates of urinary retention post-
PB. Furthermore, this study attempts to establish the utility of routine, post-PB cystoscopy, by doc-
umenting the incidence of ﬁnding signiﬁcant pathology on cystoscopy.
Materials and methods: Between January 2003 and January 2007, 225 patients deemed by their physician
to be candidates for PB alone were recruited to the study. Patients who had external beam radiation
therapy and/or androgen deprivation therapy were excluded. Preimplant International Prostate Symp-
tom Score (IPSS), urinary quality of life score, urine leakage score, Sexual Health Inventory for Men score,
and Radiation Therapy Oncology Group Bowel Health Inventory Scores were obtained. Patients were
assigned to one of the following three groups: intraoperative rigid cystoscopy, ﬂexible cystoscopy, or no
cystoscopy following PB. Patient self-administered questionnaires were given to the patient in the re-
covery room after PB. These questionnaires evaluated the intensity, type, and duration of urinary
symptoms associated with the ﬁrst four urinations post-PB. All patients were seen on postoperative Day
1 when the surveys were retrieved. Patients were then followed up every 3 months. Acute urinary
retention (AUR) was documented in the follow ups. Frequencies of signiﬁcant pathology (deﬁned as
bladder tumor, urethral stricture, or large blood clots) were documented at the time of cystoscopy. AUR
rates were also evaluated by the isotope used (I125, Pd103, or Cs131).
Results: A total of 225 patients were enrolled into this study, but only 194 patients could be analyzed for
dysuria. Thirty-one patients were excluded from analysis (6, 13, and 12 patients from the rigid, ﬂexible,
and no cystoscopy groups, respectively). These patients did not return the questionnaire, or were in
retention, and thus did not have dysuria scores to report. Baseline characteristics for the 194 patients in
terms of preimplant IPSS, quality of life, prostate volume, and isotope used were well balanced between
all three groups. There were no signiﬁcant differences in dysuria between the three cystoscopy groups at
any time point following PB. The mean dysuria score across all time points was 5.5 of 10, with 0 repre-
senting “no pain” and 10 representing “the worst possible pain.” Pain was most often characterized as
“burning” (78%), whereas dysuria most commonly was “only during urination” (56%). AUR rates (6.8
e9.5%) and duration of catheter dependence (10.5e19 days) were not found to be signiﬁcantly different
between the assigned groups. When results were stratiﬁed by isotope, patients treated with I125, Pd103,
and Cs131 seeds experienced a 6%, 14%, and 0% retention rate, respectively. The I125 and Pd103 patients had
similar pretreatment IPSS and prostate volumes. Seven percent of patients undergoing cystoscopy had
signiﬁcant ﬁndings. The most common ﬁnding was “clots thought too large to void” (3%). Seeds in the
bladder/urethra occurred in 1% of cases. Only 0.7% of patients were found to harbor unsuspected bladder
tumors.ncology, Indiana University, 535 Barnhill Drive, RT 041, Indianapolis, IN 46202-5289, USA.
ociation. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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patients in the rigid, ﬂexible, and no cystoscopy groups. Larger blood clots that may have been difﬁcult to
void, seeds in the bladder and/or urethra, and other abnormalities were found in 7% of patients who had
cystoscopy. This may suggest that cystoscopy may be worthwhile post-PB. The incidence of AUR was not
signiﬁcantly different between the three cohorts.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Permanent prostate radioactive seed implantation has become a
well-accepted primary treatment for clinically localized prostate
cancer. Multiple reports demonstrate that well-performed
brachytherapy at leading institutions could result in 5-, 10-, and
15-year biochemical relapse-free survival (BRFS) rates equal to
those reported by top centers using radical prostatectomy or in-
tensity modulated radiation therapy.1e19 Although the risk of in-
continence and impotence following brachytherapy is relatively
low compared with radical prostatectomy, one of the major goals of
brachytherapy currently is to further reduce any and all toxicities of
treatment, including short-term side effects such as dysuria and
acute urinary retention (AUR).20e24
Following permanent seed prostate brachytherapy (PB), pa-
tients often experience moderate to severe dysuria on initial uri-
nations.25 It has been a common, although not a universal, practice
to use rigid cystoscopy at the end of an implant procedure to
evaluate the overall condition of the urethra and bladder, and to
evacuate any large blood clots and/or seeds.26 One possible factor
contributing to the dysuria and other postoperative urinary
symptoms is the introduction of the rigid cystoscope. This may
cause minor trauma to the urethra and prostate. In this regard,
ﬂexible cystoscopy can be utilized as it has the potential advantage
of causing less trauma, and therefore, fewer or less intense post-
operative urinary symptoms. Flexible cystoscopy with local anes-
thesia has previously been demonstrated to have signiﬁcantly less
postprocedure voiding discomfort than rigid cystoscopy under a
general anesthetic.27
Cystoscopy is a well-accepted and widely used diagnostic and
therapeutic tool in the ﬁeld of urology, but currently little infor-
mation is available about its potential risks and beneﬁts for patients
receiving PB.
The primary objectives of this study were to examine whether
or not there are any signiﬁcant differences between rigid, ﬂexible
cystoscopy, and no cystoscopy on postoperative dysuria and AUR.
The secondary objectives were to document the need for cystos-
copy in patients undergoing PB by documenting the incidence of
signiﬁcant pathology.2. Materials and methods
The Swedish Medical Center Investigational Review Board and
Western Investigational Review Board approved this prospective
trial. A total of 225 patients undergoing PB as monotherapy were
treated with I125, Pd103, or Cs131. Isotope selection was determined
by the treating physician. To reduce confounding factors, we did not
include patients receiving supplemental external beam radiation
therapy or androgen ablation therapy. In addition, patients with a
history of prior transurethral resection of the prostate were
excluded. At initial consultation, all patients ﬁlled out an Interna-
tional Prostate Symptom Score (IPSS) form. All patients were
instructed to begin alpha blockers at least 4 days prior to the
implant procedure. Preoperative and postoperative alpha blockerswere used in 197 patients, preoperative alpha blocker use was not
known in 20 patients, and postoperative alpha blockers were not
needed in three patients. PB was performed using the standard
Seattle transperineal, transrectal ultrasound, and template-guided
preplan techniques, as described previously.26,28 After informed
consent was obtained, study participants were organized into the
following cohorts: rigid cystoscopy, ﬂexible cystoscopy, and no
cystoscopy. If the urologist was unable to carry out a satisfactory
ﬂexible cystoscopy, a rigid cystoscopy using a 22-Fr cystoscope was
performed. Patients were converted from no cystoscopy or ﬂexible
cystoscopy to rigid cystoscopy if pathological ﬁndings such as large
blood clots, bladder tumors, or seeds embedded into the urethral
mucosawere identiﬁed. Patients were ultimately grouped based on
what technique they actually received and not based on what they
were assigned to receive initially.
Prior to discharge from the ambulatory surgical center (ASC),
patients had their Foley catheter removed and were given a survey
form on which they noted the intensity and quality of the dysuria
they experienced on the ﬁrst four urinations after discharge. On
postoperative Day 1, patients underwent a noncontrast prostate
computer tomography scan for postoperative dosimetry purposes.
Patients were then seen by their treating physician, turned in their
dysuria scoring form, and ﬁlled out an IPSS form for comparison
with their pretreatment IPSS form. Routine follow up continued
every 3 months, alternating with the urologist and radiation
oncologist for the 1st year and then every 6 months thereafter. At
each visit, an IPSS form was ﬁlled out and the patient was inter-
viewed to determine whether or not AUR had occurred in the
interim. For out-of-town patients, follow up was arranged via
telephone interviews and IPSS forms were faxed. The completed
forms were then reviewed by their physicians. Follow-up docu-
mentation was obtained on all patients.3. Results
Two hundred and twenty patients were included in the study;
74 patients were assigned to the rigid cystoscopy group, 88 to the
ﬂexible cystoscopy group, and 58 to the no cystoscopy group. Iso-
topes used were I125 (161 patients), Pd103 (56 patients), and Cs131 (3
patients). Several patients assigned to the no cystoscopy group or
the rigid cystoscopy group demanded ﬂexible cystoscopy on the
day of the procedure. Three patients supposed to undergo rigid
cystoscopy were converted to ﬂexible cystoscopy because of their
preference and/or a lack of available sterile rigid scope. Seven pa-
tients initially assigned to the no cystoscopy group were later
converted to receive ﬂexible cystoscopy due to their preference
and/or difﬁculty in catheterization. No signiﬁcant difference in
dysuria intensity was noted between the three treatment arms on
the ﬁrst four urinations after discharge from the ASC (Table 1). The
majority of patients experienced moderate to severe dysuria
(Table 2). Typically, dysuria only occurred during urination; it rarely
lastedmore than 5minutes after urination (Table 3). A vast majority
of urinations were described as “burning” or “sharp” in quality
(Table 1). Dysuria only lasted 1 day in 173/194 (89%) of the patients.
Table 1
Different types of dysuria pain described by the patients in each randomized group
during the ﬁrst four urinations.
Description
of pain
Rigid cystoscopy
group (%)
Flexible cystoscopy
group (%)
No cystoscopy
group (%)
Sharp 23 22 28
Burning 78 80 70
Throbbing 3 2 2
Dull 4 5 12
Table 2
Pathology found at time of cystoscopy.
Major pathology No.
Clot too large to void 5
Bladder cancer 1
Seeds in bladder/urethra 2
Urethral/meatal stricture 3
Total 11
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tients (11%).
When comparing dysuria scores between the three arms, there
was no statistically signiﬁcant difference among the three arms of
the study (p > 0.05).
Patients who received rigid, ﬂexible, or no cystoscopy all had the
same rate of AUR (approximately 9%). Patients who received I125
monotherapy had less incidence of AUR (6%) than those who
received Pd103 monotherapy (14%).
There was one bladder malignancy noted on cystoscopy, and
two cases where patients were converted to rigid cystoscopy from
planned ﬂexible or no cystoscopy due to blood clots thought to be
potentially too large to evacuate otherwise. On planned rigid
cystoscopy, there were two patients with seeds embedded in the
urethral mucosa, one patient with an early bladder cancer, ﬁve
patients with large blood clots, and three patients with benign le-
sions biopsied at cystoscopy (Table 2).4. Discussion
PB, radical prostatectomy, and external beam radiation therapy
are the three most common deﬁnitive treatments for localized
prostate cancer. Much debate exists as to which of these therapies
is “superior” in terms of both BRFS and acute and long-term
morbidity. The practitioners of these therapies continue to report
BRFS outcomes and increasingly report quality of life outcomes.
Quality of life outcomes are most reliable when validated patient
self-administered questionnaires are utilized.21,28,29 In an attempt
to evaluate, characterize, and decrease the intensity of immediate
post-PB dysuria, we analyzed patients’ responses between rigid,
ﬂexible, and no cystoscopy and had the study participants ﬁll outTable 3
Acute urinary retention rates stratiﬁed by isotope.
I125 (161) Pd103 (56) Cs131 (3)
AUR (No. of patients needing
catheter), n (%)
11 (6.8) 7 (12.5) 0
AUR median duration
(postoperation), d
30 11 n/a
Median dysuria score (based on the
ﬁrst 4 urinations)
5 6 6
AUR mean pretreatment TRUS (cm3) 36.7 29.8 n/a
AUR mean pretreatment IPSS 4.5 5.4 n/a
AUR mean pretreatment QOL 3.3 3.6 n/a
AUR ¼ acute urinary retention; IPSS ¼ International Prostate Symptom Score;
QOL ¼ quality of life; TRUS ¼ transrectal ultrasound.questionnaires related to urinary functioning before and after
postprostatectomy incontinence.
We expected that those who underwent a rigid cystoscopy at
the time of PB would have more severe dysuria than those under-
going ﬂexible cystoscopy or no cystoscopy. However, the patients
reported no signiﬁcant difference in severity, character, or duration
of dysuria between the three arms of the trial.
One criticism of this prospective phase III study is the unequal
number of patients in the three arms. Unequal distribution
occurred due to several patients demanding (just prior to anes-
thesia) rigid cystoscopy rather than what they had been random-
ized to initially. We have reported on their outcomes based on how
they were actually treated rather than on their intended treatment.
In fact, the outcomes were no different whether reported by
intention to treat or the actual treatment arm. Another weakness of
this study is that some patients did not completely ﬁll out their
postoperative dysuria questionnaires. However, the questions that
were answered were consistent between the three treatment arms.
It seems unlikely that the study result would have differed signif-
icantly from that which is reported here even if 100% of the ques-
tionnaires had been ﬁlled out. All patients received a Foley catheter
before the start of the implant procedure. This may in fact lead to
some confounding of the levels of dysuria experienced by the
participants. In addition, the three treatment arms of the study
experienced approximately the same level of dysuria. Although the
study was set up to detect the effect of various cystoscopy modal-
ities on dysuria, it appears that most dysuria is due to the seed
implantation brachytherapy itself.
This report prospectively documents a high incidence of moder-
ate to severe dysuria in the ﬁrst 24 hours following PB. The intensity,
duration, and quality of the dysuria were not inﬂuenced by whether
the patient received rigid or ﬂexible or no cystoscopy during the PB
procedure. Only 11% experienced dysuria formore than 24 hours and
only 3% experienced it for more than 3months. The dysuria typically
occurred during the act of urination, but in 10% it lasted more than 5
minutes after the completion of urination. In most cases, dysuria
responded to nonsteroidal anti-inﬂammatory medications.
AUR occurred in 9% of the patients in this study. The incidence of
AUR was not inﬂuenced by which arm of the study the patient was
in. Patients treated with Pd103 PB experienced a 14% incidence of
AUR, whereas those treated with I125 PB experienced only a 6%
incidence. The higher rate of AUR experienced by the Pd103 patients
is likely due to the shorter half-life of Pd103 (17 days), compared
with I125 (60 days), for radioactive seeds. As a result, we adminis-
tered a higher effective dose to the prostate, which subsequently
caused more interstitial edema after seed implantation. The typical
predictors of AUR were well balanced between the isotopes
(Table 3).
5. Conclusion
Cystoscopy at the time of PB does not inﬂuence the incidence,
duration, or severity of immediate posttreatment dysuria or AUR.
Dysuria is typically moderate to severe, occurs during the act of
urination and rarely persists more than 1 day post-PB.
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